- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 14:30 | Vodafone settles contingent liability agreement with Vi | ||
| 14:30 | NANO Nuclear signs MOU with University of Illinois for microreactor | ||
| 14:30 | Delcath's HEPZATO shows consistent efficacy across patient subgroups | ||
| 14:30 | NANO Nuclear signs MOU for microreactor at University of Illinois | ||
| 14:30 | BLAQclouds to spin out property group with January distribution | ||
| 14:30 | Linamar completes €45 million acquisition of Georg Fischer's Leipzig plant | ||
| 14:30 | Nano Labs expands BNB holdings to $112 million, begins share buyback | ||
| 14:30 | FDA rejects Corcept's relacorilant for hypercortisolism hypertension | ||
| 14:30 | IWG launches $50 million share buyback program for 2026 | ||
| 14:30 | Tower Semiconductor stock rating downgraded by Wedbush on valuation | ||
| 14:30 | Freedom Capital Markets initiates Buy rating on International Bancshares stock | ||
| 14:30 | Praxis Precision Medicines stock gains as TD Cowen reiterates Buy on FDA breakthrough status | ||
| 14:30 | GlobalFoundries stock rating downgraded to Neutral by Wedbush | ||
| 13:54 | Profusa expands European footprint with French distributor partnership | ||
| 13:54 | Capstone extends revolving credit facility with Berkshire Bank | ||
| 13:42 | BMO Capital resumes WSP Global stock coverage with Outperform rating | ||
| 13:42 | MakeMyTrip stock rating reiterated at Overweight by Morgan Stanley | ||
| 13:42 | Morgan Stanley sees China's December PMI strength driven by exports and policy | ||
| 13:42 | H.C. Wainwright reiterates Buy rating on Bright Minds stock with $115 target | ||
| 13:42 | Raymond James reiterates Outperform rating on Inflarx stock at $9 target | ||
| 13:30 | Pharos Energy receives $20 million payment from Egypt's EGPC | ||
| 13:30 | Electric Guitar's half-year profit hits £0.9m following CVA debt clearance | ||
| 13:30 | Wizz Air creates new financial performance committee led by Broderick | ||
| 13:30 | FDA grants priority review for Axsome's Alzheimer's agitation drug | ||
| 13:30 | BioAtla secures $40 million for phase 3 cancer drug development |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .